Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...

Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...